Key facts
- This page summarizes Allen Baharaff's Form 3 filing for Galmed Pharmaceuticals Ltd. (GLMD).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 07:45.
Allen Baharaff - 18 Mar 2026 Form 3 Insider Report for Galmed Pharmaceuticals Ltd. (GLMD)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- GLMD
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Allen Baharaff
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Allen Baharaff filed Form 3 for Galmed Pharmaceuticals Ltd. (GLMD) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001630334
Primary reporting owner
Baharaff Allen
- Relationship
- Chief Executive Officer, Director
- Address
- C/O MEITAR LAW OFFICES, 16 ABBA HILLEL SILVER RD., RAMAT GAN, ISRAEL
- Signature
- /s/ Allen Baharaff
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GLMD
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 103,047
- Date
- 18 Mar 2026
- Ownership
- Direct
GLMD
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18
- Date
- 18 Mar 2026
- Ownership
- See Footnote
- Footnotes
- F1
GLMD
holding
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,889
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F2
GLMD
holding
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 96,666
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F3
GLMD
holding
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 100,000
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GLMD
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,222
- Exercise price
- $599.40
GLMD
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,222
- Exercise price
- $921.60
GLMD
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,222
- Exercise price
- $2080.80
GLMD
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,805
- Exercise price
- $0.002000
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Ordinary shares beneficially owned by Reporting Person's spouse.
Footnote F2
These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.
Footnote F3
These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.
Footnote F4
These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.